中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(3): 453-456

Epidemiology and clinical outcome of chronic hepatitis B virus infection and metabolic dysfunction

DOI: 10.12449/JCH240303

  • Department of Hepatology，The First Affiliated Hospital of Fujian Medical University，Fuzhou 350004，China

Research funding:

National Natural Science Foundation of China Young Scientist Fund (82300652);

Natural Science Foundation of Fujian Province (2022J01700);

Clinical Research Center for Liver and Intestinal Diseases of Fujian Province (2021Y2006)

More Information
  • Corresponding author: ZHENG Qi， bei0825@163.com （ORCID： 0000-0001-8006-7069 ）
  • Received Date: 2024-01-09
  • Accepted Date: 2024-01-28
  • Published Date: 2024-03-20
    Abstract
  • Chronic hepatitis B virus （HBV） infection is a worldwide public health issue and a leading cause of liver fibrosis， liver cirrhosis， liver failure， and primary liver cancer in China. The incidence rate of nonalcoholic fatty liver disease （NAFLD） is gradually increasing with the improvement in the living standards of people and the changes in dietary structure. Population-based studies have found that HBV infection can influence the development of NAFLD， but the mechanism remains unknown. Hepatic steatosis can also influence the expression of HBV serum pathogenic indicators， and its combination with NAFLD and other metabolic dysfunction diseases can increase the risk of liver fibrosis， liver cirrhosis， and liver cancer. Chronic HBV infection is closely associated with metabolic dysfunction， and more studies are needed in the future to better understand related mechanisms， so as to provide a theoretical foundation for clinical diagnosis and treatment.

     

    • FullText(HTML)
  • loading
    • References(46)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(2022 version)[J]. Chin J Infect Dis, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41( 1): 3- 28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
    [2]
    World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016- 2021: actions for impact[EB/OL].( 2021-05-20). https://iris.who.int/handle/10665/341412. https://iris.who.int/handle/10665/341412
    [3]
    JENG WJ, LIAW YF. Finite antiviral therapy in chronic hepatitis B patients with cirrhosis[J]. Semin Liver Dis, 2021, 41( 3): 349- 357. DOI: 10.1055/s-0041-1729973.
    [4]
    RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851- 861. DOI: 10.1016/S2468-1253(22)00165-0.
    [5]
    WONG VW, EKSTEDT M, WONG GL, et al. Changing epidemiology, global trends and implications for outcomes of NAFLD[J]. J Hepatol, 2023, 79( 3): 842- 852. DOI: 10.1016/j.jhep.2023.04.036.
    [6]
    YOUNOSSI ZM, GOLABI P, PAIK JM, et al. The global epidemiology of nonalcoholic fatty liver disease(NAFLD) and nonalcoholic steatohepatitis(NASH): a systematic review[J]. Hepatology, 2023, 77( 4): 1335- 1347. DOI: 10.1097/HEP.0000000000000004.
    [7]
    LUUKKONEN PK, QADRI S, AHLHOLM N, et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease[J]. J Hepatol, 2022, 76( 3): 526- 535. DOI: 10.1016/j.jhep.2021.10.013.
    [8]
    YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64( 1): 73- 84. DOI: 10.1002/hep.28431.
    [9]
    HUANG DQ, EL-SERAG HB, LOOMBA R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 4): 223- 238. DOI: 10.1038/s41575-020-00381-6.
    [10]
    ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202- 209. DOI: 10.1016/j.jhep.2020.03.039.
    [11]
    SHI YW, YANG RX, FAN JG. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion[J]. World J Gastroenterol, 2021, 27( 26): 3971- 3983. DOI: 10.3748/wjg.v27.i26.3971.
    [12]
    THOMOPOULOS KC, ARVANITI V, TSAMANTAS AC, et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis[J]. Eur J Gastroenterol Hepatol, 2006, 18( 3): 233- 237. DOI: 10.1097/00042737-200603000-00002.
    [13]
    MACHADO MV, OLIVEIRA AG, CORTEZ-PINTO H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients[J]. J Gastroenterol Hepatol, 2011, 26( 9): 1361- 1367. DOI: 10.1111/j.1440-1746.2011.06801.x.
    [14]
    ZHENG Q, ZOU B, WU Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2021, 54( 9): 1100- 1109. DOI: 10.1111/apt.16595.
    [15]
    JIANG D, CHEN C, LIU X, et al. Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis[J]. Ann Transl Med, 2021, 9( 23): 1718. DOI: 10.21037/atm-21-3052.
    [16]
    YANG M, WEI L. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia[J]. Liver Int, 2022, 42( 9): 1981- 1990. DOI: 10.1111/liv.15252.
    [17]
    XIONG J, ZHANG H, WANG Y, et al. Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis[J]. Oncotarget, 2017, 8( 63): 107295- 107302. DOI: 10.18632/oncotarget.22364.
    [18]
    WANG CC, KAO JH. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study[J]. Hepatology, 2017, 66( 2): 681. DOI: 10.1002/hep.29252.
    [19]
    WONG VW, WONG GL, CHU WC, et al. Hepatitis B virus infection and fatty liver in the general population[J]. J Hepatol, 2012, 56( 3): 533- 540. DOI: 10.1016/j.jhep.2011.09.013.
    [20]
    CHENG YL, WANG YJ, KAO WY, et al. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up[J]. PLoS One, 2013, 8( 8): e72049. DOI: 10.1371/journal.pone.0072049.
    [21]
    HUANG J, JING M, WANG C, et al. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: A population-based study[J]. J Med Virol, 2020, 92( 8): 1191- 1197. DOI: 10.1002/jmv.25621.
    [22]
    YU MW, LIN CL, LIU CJ, et al. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors[J]. J Formos Med Assoc, 2022, 121( 8): 1478- 1487. DOI: 10.1016/j.jfma.2021.10.014.
    [23]
    CHEN YY, FANG WH, WANG CC, et al. Increased body fat percentage in patients with hepatitis B and C virus infection[J]. PLoS One, 2018, 13( 7): e0200164. DOI: 10.1371/journal.pone.0200164.
    [24]
    LEI S, CHEN S, ZHAO X, et al. Hepatitis B virus infection and diabetes mellitus: the Kailuan prospective cohort study in China[J]. Hepatol Int, 2020, 14( 5): 743- 753. DOI: 10.1007/s12072-020-10086-2.
    [25]
    JOO EJ, CHANG Y, YEOM JS, et al. Chronic hepatitis B virus infection and risk of dyslipidaemia: A cohort study[J]. J Viral Hepat, 2019, 26( 1): 162- 169. DOI: 10.1111/jvh.13014.
    [26]
    BAKER F ABU, DAVIDOV Y, ISRAEL A, et al. Chronic hepatitis B infection and diabetes mellitus: a double liver trouble?[J]. Minerva Med, 2023, 114( 5): 658- 666. DOI: 10.23736/S0026-4806.23.08428-8.
    [27]
    KIM K, CHOI S, PARK SM. Association of fasting serum glucose level and type 2 diabetes with hepatocellular carcinoma in men with chronic hepatitis B infection: A large cohort study[J]. Eur J Cancer, 2018, 102: 103- 113. DOI: 10.1016/j.ejca.2018.07.008.
    [28]
    WANG MM, WANG GS, SHEN F, et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J]. Dig Dis Sci, 2014, 59( 10): 2571- 2579. DOI: 10.1007/s10620-014-3180-9.
    [29]
    CHU CM, LIN DY, LIAW YF. Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without[J]. Dig Dis Sci, 2013, 58( 1): 275- 281. DOI: 10.1007/s10620-012-2343-9.
    [30]
    CHU CM, LIN DY, LIAW YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus(HBV) surface antigen in chronic HBV infection?[J]. Int J Obes(Lond), 2007, 31( 5): 871- 875. DOI: 10.1038/sj.ijo.0803479.
    [31]
    FUNG J, YUEN MF, LAI CL. The role of steatosis in HBsAg seroclearance for patients with chronic hepatitis B infection: fact or fiction?[J]. Dig Dis Sci, 2013, 58( 1): 20- 22. DOI: 10.1007/s10620-012-2441-8.
    [32]
    MAK LY, HUI RW, FUNG J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B[J]. J Hepatol, 2020, 73( 4): 800- 806. DOI: 10.1016/j.jhep.2020.05.040.
    [33]
    CHAN AW, WONG GL, CHAN HY, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B[J]. J Gastroenterol Hepatol, 2017, 32( 3): 667- 676. DOI: 10.1111/jgh.13536.
    [34]
    LEE YB, HA Y, CHON YE, et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B[J]. Clin Mol Hepatol, 2019, 25( 1): 52- 64. DOI: 10.3350/cmh.2018.0040.
    [35]
    MAO X, CHEUNG KS, PENG C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis[J]. Hepatology, 2023, 77( 5): 1735- 1745. DOI: 10.1002/hep.32792.
    [36]
    VAN KLEEF LA, CHOI H, BROUWER WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B[J]. JHEP Rep, 2021, 3( 5): 100350. DOI: 10.1016/j.jhepr.2021.100350.
    [37]
    LIN S, HUANG J, WANG M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world[J]. Liver Int, 2020, 40( 9): 2082- 2089. DOI: 10.1111/liv.14548.
    [38]
    ZHAO J, ZHAO Y, WANG H, et al. Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: a cross-sectional study[J]. Nutr J, 2011, 10: 49. DOI: 10.1186/1475-2891-10-49.
    [39]
    MARENGO A, ROSSO C, BUGIANESI E. Liver cancer: connections with obesity, fatty liver, and cirrhosis[J]. Annu Rev Med, 2016, 67: 103- 117. DOI: 10.1146/annurev-med-090514-013832.
    [40]
    LIU F, GUO Z, DONG C. Influences of obesity on the immunogenicity of Hepatitis B vaccine[J]. Hum Vaccin Immunother, 2017, 13( 5): 1014- 1017. DOI: 10.1080/21645515.2016.1274475.
    [41]
    KHALILI M, SHUHART MC, LOMBARDERO M, et al. Relationship between metabolic syndrome, alanine aminotransferase levels, and liver disease severity in a multiethnic North American cohort with chronic hepatitis B[J]. Diabetes Care, 2018, 41( 6): 1251- 1259. DOI: 10.2337/dc18-0040.
    [42]
    WONG GL, WONG VW, CHOI PC, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B[J]. Gut, 2009, 58( 1): 111- 117. DOI: 10.1136/gut.2008.157735.
    [43]
    WONG GL, CHAN HL, YU Z, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations[J]. Aliment Pharmacol Ther, 2014, 39( 8): 883- 893. DOI: 10.1111/apt.12658.
    [44]
    CHAO LT, WU CF, SUNG FY, et al. Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort[J]. Carcinogenesis, 2011, 32( 6): 876- 881. DOI: 10.1093/carcin/bgr058.
    [45]
    CAMPBELL C, WANG T, MCNAUGHTON AL, et al. Risk factors for the development of hepatocellular carcinoma(HCC) in chronic hepatitis B virus(HBV) infection: a systematic review and meta-analysis[J]. J Viral Hepat, 2021, 28( 3): 493- 507. DOI: 10.1111/jvh.13452.
    [46]
    YU MW, LIN CL, LIU CJ, et al. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study[J]. Gastroenterology, 2017, 153( 4): 1006- 1017. e 5. DOI: 10.1053/j.gastro.2017.07.001.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (367) PDF downloads(86) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return